<?xml version="1.0" encoding="UTF-8" standalone="no"?><rss xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" version="2.0"><channel><title>Claremont Creek Ventures</title><description>Lifecycle Venturing</description><managingEditor>noemail@noemail.org (Ted Driscoll)</managingEditor><pubDate>Thu, 7 Mar 2019 19:24:26 GMT</pubDate><generator>WordPress https://wordpress.org/</generator><link>https://claremontcreek.com</link><language>en-us</language><item><title>Is Medicine a Big Data Problem?</title><link>https://claremontcreek.com/medicine-big-data-problem/</link><category>Bioinformatics</category><category>Digital Healthcare</category><category>Guest post</category><category>Healthcare IT</category><category>bioinformatics</category><category>chromosone screening</category><category>gene disorder testing</category><category>genetic screening</category><category>healthcare</category><category>innovation</category><category>Personalized Pharmacology</category><category>words-of-wisdom</category><author>noemail@noemail.org (Ted Driscoll)</author><pubDate>Fri, 21 Mar 2014 23:24:59 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3949</guid><description>Human beings are big data. We aren’t just 175 pounds of meat and bone. We aren’t just piles of hydrogen and carbon and oxygen.  What makes us all different is how it’s all organized and that is information.
We can no longer treat people based on simple numbers like weight, pulse, blood pressure, and temperature. What makes us different is much more complicated than that.</description></item><item><title>Harsh Patel Joins Claremont Creek Ventures</title><link>https://claremontcreek.com/harsh-patel-joins-claremont-creek-ventures/</link><category>Events/News</category><category>News</category><author>noemail@noemail.org (Paul Straub)</author><pubDate>Wed, 15 Jan 2014 12:30:27 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3933</guid><description>I’m thrilled to welcome Harsh Patel as a Partner at Claremont Creek Ventures. We believe people and relationships form the core elements of any successful entrepreneurial venture. We typically get involved early in a company’s development, when a product is nascent and a market may barely exist. One of the distinguishing characteristics about Harsh is that he excels in the same type of early-stage, relationship-oriented investing that we value. </description></item><item><title>Harveen Sethi Joins Claremont Creek Ventures as Associate</title><link>https://claremontcreek.com/harveen-sethi-joins-claremont-creek-ventures-associate/</link><category>News</category><author>noemail@noemail.org (Ted Driscoll)</author><pubDate>Mon, 23 Dec 2013 09:25:29 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3912</guid><description>I am excited to announce today that Harveen Sethi has joined the CCV team as an associate. She will be working closely with Brad Webb and me. Harveen is passionate about impactful disruptive innovation, especially in shaping the next frontier of healthcare. She is particularly enthusiastic about the potential of big data analytics and technology in advancing predictive diagnostics and personalized medicine. These are [&amp;#8230;]</description></item><item><title>Ted Driscoll&amp;#8217;s WSJ interview: 23andMe Flap With FDA Just a Bump in the Road, One Genetics-Testing Investor Says</title><link>https://claremontcreek.com/ted-driscolls-wsj-interview-23andme-flap-fda-just-bump-road-one-genetics-testing-investor-says/</link><category>AssureRx</category><category>Bioinformatics</category><category>Clinical IT</category><category>Digital Healthcare</category><category>Healthcare IT</category><category>interviews</category><category>Natera</category><category>News</category><category>Portfolio Press</category><category>bioinformatics</category><category>chromosone screening</category><category>genetic screening</category><category>government policies</category><category>market uncertainty</category><category>Personalized Pharmacology</category><category>words-of-wisdom</category><author>noemail@noemail.org (Claremont Creek Alerts)</author><pubDate>Tue, 17 Dec 2013 00:22:55 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3905</guid><description>source:   by Timothy Hay When the Food and Drug Administration told personal-genetics company 23andMe Inc. in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could be a devastating blow to an emerging area of medicine that holds promise for better health outcomes. But it was more of [&amp;#8230;]</description></item><item><title>Assurex Health Launches Collaboration with  Canadian Mental Health Center</title><link>https://claremontcreek.com/assurex-health-launches-collaboration-canadian-mental-health-center/</link><category>AssureRx</category><category>Bioinformatics</category><category>Clinical IT</category><category>Digital Healthcare</category><category>Healthcare IT</category><category>News</category><category>Portfolio Press</category><category>bioinformatics</category><category>genetic screening</category><category>healthcare</category><category>pharmacogenomics</category><author>noemail@noemail.org (Brad Webb)</author><pubDate>Sat, 30 Nov 2013 05:51:22 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3897</guid><description>Our portfolio company Assurex Health just announced the creation of a partnership with Canada&amp;#8217;s Center for Addiction and Mental Health (CAMH), one of the world&amp;#8217;s leading research centers in the area of addiction and mental health and Canada&amp;#8217;s largest mental health teaching hospital. CAMH will offer to Canadian citizens the firm&amp;#8217;s pharmacogenomic test, GeneSight, which [&amp;#8230;]</description></item><item><title>Shotspotter&amp;#8217;s New Technology Grabs Feature On CNN&amp;#8217;s Erin Burnett Show</title><link>https://claremontcreek.com/shotspotters-new-technology-grabs-feature-on-cnns-erin-burnett-show/</link><category>News</category><category>Physical Security</category><category>Portfolio Press</category><category>Shotspotter</category><category>innovation</category><author>noemail@noemail.org (Randy Hawks)</author><pubDate>Tue, 26 Nov 2013 23:49:56 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3893</guid><description>This story about Claremont Creek Ventures' portfolio Shotspotter covers how their new technology could improve how fast police respond to shootings inside schools and other buildings</description></item><item><title>ShotSpotter Launches SiteSecure: Indoor Gunshot Location Detection Solution</title><link>https://claremontcreek.com/shotspotter-launches-sitesecure-indoor-gunshot-location-detection-solution/</link><category>News</category><category>Physical Security</category><category>Portfolio Press</category><category>Security</category><category>Shotspotter</category><author>noemail@noemail.org (Randy Hawks)</author><pubDate>Fri, 15 Nov 2013 18:01:45 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3886</guid><description>This week was very important for our portfolio company ShotSpotter. They launched an indoor gunshot location detection system, SiteSecure. ShotSpotter locates the hot spots of gun violence – it can detect everything from the exact location of where the gun was fired to how many rounds were fired. </description></item><item><title>Smartzip Offers New Facebook App That&amp;#8217;s All About Engagement</title><link>https://claremontcreek.com/smartzip-offers-new-facebook-app-thats-engagement/</link><category>News</category><category>Portfolio Press</category><category>SmartZip</category><author>noemail@noemail.org (Randy Hawks)</author><pubDate>Mon, 11 Nov 2013 09:05:38 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3881</guid><description>CCV's portfolio company SmartZip Analytics, Inc.--the leader in analytics-driven targeted marketing for the real estate industry---today announced the release of a new Facebook app for SmartTargeting, their flagship predictive marketing platform.</description></item><item><title>Claremont Creek Ventures Has Two Portfolio Companies Honored by White   House for “Champions of Change” Award</title><link>https://claremontcreek.com/claremont-creek-ventures-two-portfolio-companies-honored-white-house-champions-change-award/</link><category>Awards</category><category>Bioinformatics</category><category>Clean Power Finance</category><category>Clinical IT</category><category>Digital Healthcare</category><category>Energy Conservation &amp; Management</category><category>Healthcare IT</category><category>News</category><category>NuMedii</category><category>Portfolio Press</category><category>awards</category><category>innovation</category><author>noemail@noemail.org (Claremont Creek Alerts)</author><pubDate>Mon, 11 Nov 2013 08:44:14 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3878</guid><description>&amp;#160; This week Nat Kreamer, president and chief executive officer of CCV portfolio company Clean Power Finance, was honored at a White House ceremony with the “Champions of Change”/ “Veterans in Clean Energy and Climate Security” award. Atul Butte co-founder of Numedii, another CCV portfolio company, was also honored for the same “Champion of Change” [&amp;#8230;]</description><thr:total xmlns:thr="http://purl.org/syndication/thread/1.0">1</thr:total></item><item><title>Our newest portfolio company Building Robotics closed a seed round today at $1.14M</title><link>https://claremontcreek.com/our-newest-portfolio-company-building-robotics-closed-a-seed-round-today-at-1-14m/</link><category>Building Robotics</category><category>Energy Conservation &amp; Management</category><category>News</category><category>Portfolio Companies</category><category>cleantech</category><category>energy conservation</category><category>energy tech</category><category>greentech</category><category>innovation</category><author>noemail@noemail.org (Hans Anders)</author><pubDate>Thu, 7 Nov 2013 22:31:11 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3869</guid><description>We are stoked about our newest portfolio company Building Robotics who closed a seed round today at $1.14M. Google Ventures plus many others invested with Claremont Creek Ventures, but we were the lead investor. The company had a ton of press for the announcement which you can see here: Congratulations Building Robotics !</description></item><item><title>Building Robotics, Maker of People-Centered Intelligent Software for Buildings, Announces $1.14M Seed Round</title><link>https://claremontcreek.com/building-robotics-maker-people-centered-intelligent-software-buildings-announces-1-14m-seed-round/</link><category>Energy Conservation &amp; Management</category><category>News</category><category>energy conservation</category><category>energy tech</category><category>funding</category><category>greentech</category><category>innovation</category><author>noemail@noemail.org (Claremont Creek Alerts)</author><pubDate>Thu, 7 Nov 2013 12:30:18 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3857</guid><description>Building Robotics’ initial product, Comfy, is the first to meaningfully reconnect people to the heating and cooling in their work environments, providing more comfortable spaces while saving energy. The software installs quickly and easily and is compatible with most existing building management systems, while providing occupants with a mobile and web application. It provides instant warm or cool air to people, while incorporating their usage patterns and feedback into a machine-learning algorithm that reduces energy.</description></item><item><title>Thomson Reuters and NuMedii Launch Initiative for Drug Discovery</title><link>https://claremontcreek.com/thomson-reuters-numedii-launch-initiative-drug-discovery/</link><category>Bioinformatics</category><category>Clinical IT</category><category>Digital Healthcare</category><category>News</category><category>NuMedii</category><category>Portfolio Companies</category><category>Portfolio Press</category><category>bioinformatics</category><category>healthcare</category><category>innovation</category><category>Personalized Pharmacology</category><author>noemail@noemail.org (Brad Webb)</author><pubDate>Wed, 6 Nov 2013 08:16:07 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3847</guid><description>Our portfolio company NuMedii just announced a groundbreaking collaboration with Thomson Reuters, the world’s leading information provider for businesses. The Thomson Reuters Science division has quietly been aggregating an enormous database of biological, clinical, and pharmacological information over the past few years. As a biotech startup, NuMedii is focused on revolutionizing drug discovery by reducing [&amp;#8230;]</description></item><item><title>Claremont Creek Ventures portfolio company Shotspotter  was featured in the Washington Post</title><link>https://claremontcreek.com/claremont-creek-ventures-portfolio-company-shot-spotter-featured-in-washington-post/</link><category>News</category><category>Portfolio Press</category><category>Shotspotter</category><category>innovation</category><author>noemail@noemail.org (Randy Hawks)</author><pubDate>Mon, 4 Nov 2013 23:48:45 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3840</guid><description>It’s very cool that our portfolio company ShotSpotter was just profiled in the Washington Post (ShotSpotter detection system documents 39,000 shooting incidents in the District). In Washington DC, ShotSpotter has 300 acoustic sensors across 20 square miles of the city, covering mainly the Southeast and Northeast of the District. ShotSpotter is a unique gunfire surveillance [&amp;#8230;]</description></item><item><title>Assurex Health Publishes Seminal Paper on Pharmacogenomics</title><link>https://claremontcreek.com/assurex-health-publishes-seminal-paper-pharmacogenomics/</link><category>AssureRx</category><category>Bioinformatics</category><category>Clinical IT</category><category>Digital Healthcare</category><category>Healthcare IT</category><category>News</category><category>Portfolio Press</category><category>bioinformatics</category><category>chromosone screening</category><category>genetic screening</category><category>healthcare</category><category>innovation</category><category>Personalized Pharmacology</category><author>noemail@noemail.org (Brad Webb)</author><pubDate>Sun, 3 Nov 2013 01:17:21 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3833</guid><description>Our portfolio company Assurex Health, announced recently the publication of a groundbreaking analysis of pharmacogenomic data in the International Review of Psychiatry. The publication strongly validates the premise that the clinical use of genomic testing to help predict patient response to psychiatric medications significantly improves treatment outcomes. This is a key milestone in the continuing [&amp;#8230;]</description></item><item><title>Genalyte Receives National Cancer Institute Grant</title><link>https://claremontcreek.com/genalyte-receives-national-cancer-institute-grant/</link><category>Awards</category><category>Bioinformatics</category><category>Clinical IT</category><category>Digital Healthcare</category><category>Genalyte</category><category>Healthcare IT</category><category>News</category><category>Portfolio Press</category><category>bioinformatics</category><category>healthcare</category><category>innovation</category><author>noemail@noemail.org (Brad Webb)</author><pubDate>Mon, 21 Oct 2013 22:46:15 GMT</pubDate><guid isPermaLink="false">http://ccvreboot.claremontvc.com/?p=3818</guid><description>Our portfolio company Genalyte just announced the award of a government grant from the National Cancer Institute for the development of a  diagnostic system using Genalyte’s proprietary biomarker technology (see Genalyte Expands into Cancer Profiling with $1 Million NCI Grant to Develop Cancer Biomarker Panel). This project is a significant validation of the company’s capability [&amp;#8230;]</description></item></channel></rss>